ViiV's Two-Drug HIV Tablet Juluca Is Disruptive, Yet Uptake May Be Slow

22 Nov 2017

• By Emily Hayes

Pricing of $31,000 annually for GSK/J&J's single-tablet, two-drug HIV regimen Juluca (dolutegravir/rilpivirine) is on par with marketed fixed-dose combinations that include integrase inhibitors.

US FDA approval of ViiV Healthcare/Johnson & Johnson'stwo-drug regimen Juluca is groundbreaking for the HIV market and a big win for the sponsors, but it may take time for prescribers to get used to the paradigm change, so sales may be slow at first, Datamonitor Healthcare analysts say.

ViiV is majority-owned by GlaxoSmithKline PLC; Pfizer Inc. and Shionogi & Co. Ltd. hold stakes of 11.7%...